Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB
暂无分享,去创建一个
L. Groop | M. Laakso | A. Vaag | V. Lyssenko | O. Melander | P. Nilsson | M. Orho-Melander | C. Ladenvall | C. Forsblom | P. Groop | L. Tarnow | A. Stančáková | J. Kuusisto | A. Jonsson | E. Ahlqvist | P. Rossing | A. Gottsäter | B. Lindblad | K. Pilgaard | S. Madsbad | T. Kieffer | I. Gonçalves | M. Lajer | Maria F. Gomez | A. Edsfeldt | M. Nitulescu | C. Brøns | O. Kotova | P. Dunér | Lisa M Berglund | Anna V. Zetterqvist | S. Alkayyali | Christian Ruiz -McDavitt | L. Berglund | A. Zetterqvist | Sami Alkayyali
[1] K. Narayan,et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.
[2] G. Berglund,et al. Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[3] J. Mehta,et al. Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation , 2013, Cardiovascular Drugs and Therapy.
[4] M. Nauck,et al. Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.
[5] L. Glimcher,et al. The transcription factor NFAT4 is involved in the generation and survival of T cells. , 1998, Immunity.
[6] Thomas W. Mühleisen,et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.
[7] I. Gonçalves,et al. Changes Related to Age and Cerebrovascular Symptoms in the Extracellular Matrix of Human Carotid Plaques , 2003, Stroke.
[8] I. Gonçalves,et al. Evidence for altered inflammatory and repair responses in symptomatic carotid plaques from elderly patients. , 2014, Atherosclerosis.
[9] Kazutomo Inoue,et al. Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs , 1992, Digestive Diseases and Sciences.
[10] Xiaoping Zhou,et al. 3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. , 2000, Journal of medicinal chemistry.
[11] M. Klapholz,et al. Osteopontin in Cardiovascular Disease: A Potential Therapeutic Target , 2010, Cardiology in review.
[12] M. Renault,et al. CREB Mediates UTP-Directed Arterial Smooth Muscle Cell Migration and Expression of the Chemotactic Protein Osteopontin via Its Interaction with Activator Protein-1 Sites , 2007, Circulation research.
[13] M. Murakami,et al. Development of atherosclerosis in osteopontin transgenic mice , 2002, Heart and Vessels.
[14] P. Doevendans,et al. Local Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular Events , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[15] P. Little,et al. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. , 2008, Atherosclerosis.
[16] T. Hirano,et al. Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice , 2012, PloS one.
[17] Hyun Joon Kim,et al. Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats , 2002, Current eye research.
[18] P. Hellstrand. Long-term effects of intracellular calcium and growth factors on excitation and contraction in smooth muscle. , 1998, Acta physiologica Scandinavica.
[19] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[20] J. Holst,et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.
[21] M. Panhwar,et al. A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity , 2014, Molecular and Cellular Biology.
[22] J. Golledge,et al. Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis , 2004, Stroke.
[23] A. Gottsäter,et al. Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia , 2006, Angiology.
[24] C. Rotella,et al. Cardio Vascular Diabetology Open Access Original Investigation , 2022 .
[25] C. Forsblom,et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients , 2003, Diabetologia.
[26] Harumi Uto-Kondo,et al. Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients , 2013, Journal of the American Heart Association.
[27] E. Agardh,et al. Nuclear Factor of Activated T‐cells (NFAT) regulates osteopontin expression in arterial smooth muscle in response to diabetes‐induced hyperglycemia , 2010 .
[28] L. Groop,et al. Pleiotropic Effects of GIP on Islet Function Involve Osteopontin , 2011, Diabetes.
[29] Chunxiang Zhang,et al. The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid. , 2008, Biochimica et biophysica acta.
[30] G. Berglund,et al. The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.
[31] Julie A. Wilkins,et al. Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds* , 2001, The Journal of Biological Chemistry.
[32] R. Pederson,et al. A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] G. Berglund,et al. Blood Pressure in Relation to the Incidence of Cerebral Infarction and Intracerebral Hemorrhage: Hypertensive Hemorrhage: Debated Nomenclature Is Still Relevant , 2007, Stroke.
[34] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[35] C. Isales,et al. Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. , 2003, American journal of physiology. Endocrinology and metabolism.
[36] N. Sattar,et al. Lessons from SAVOR and EXAMINE: some important answers, but many open questions. , 2014, Journal of diabetes and its complications.
[37] G. Owens,et al. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.
[38] O. Wiklund,et al. Fatty acids modulate the effect of darglitazone on macrophage CD36 expression , 2003, European journal of clinical investigation.
[39] L. Norgren,et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.
[40] Donghong Ju,et al. Disruption of actin cytoskeleton mediates loss of tensile stress induced early phenotypic modulation of vascular smooth muscle cells in organ culture. , 2010, Experimental and molecular pathology.
[41] T. Shigematsu,et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[42] E. Agardh,et al. Vascular Cellular Adhesion Molecule-1 (VCAM-1) Expression in Mice Retinal Vessels Is Affected by Both Hyperglycemia and Hyperlipidemia , 2010, PloS one.
[43] S. Bonner-Weir,et al. Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.
[44] A. Lochner,et al. The many faces of H89: a review. , 2006, Cardiovascular drug reviews.
[45] Santiago Lamas,et al. Functional Cooperation Between Smad Proteins and Activator Protein-1 Regulates Transforming Growth Factor-&bgr;–Mediated Induction of Endothelin-1 Expression , 2003, Circulation research.
[46] L. Groop,et al. Classifying diabetes according to the new WHO clinical stages , 2004, European Journal of Epidemiology.
[47] J. Molkentin,et al. High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[48] A. Miyazaki,et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice , 2011, Diabetologia.
[49] F. Rubino,et al. Gastric Inhibitory Peptide Controls Adipose Insulin Sensitivity via Activation of cAMP-response Element-binding Protein and p110β Isoform of Phosphatidylinositol 3-Kinase* , 2011, The Journal of Biological Chemistry.
[50] K. Hirokawa,et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. , 1993, The Journal of clinical investigation.
[51] Jian Xu,et al. Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.
[52] Reiko Ohmori,et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[53] Harald Sourij,et al. Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy , 2010, PloS one.
[54] C. Isales,et al. Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells. , 2004, American journal of physiology. Endocrinology and metabolism.
[55] P. Osmark,et al. NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. , 2012, Cardiovascular research.
[56] C. Giachelli,et al. The role of osteopontin in inflammatory processes , 2009, Journal of Cell Communication and Signaling.
[57] M. Alam,et al. Gastric inhibitory polypeptide (GIP) responses in type 2 diabetes using three different antibodies. , 1993, Annals of Saudi medicine.
[58] A. Miyazaki,et al. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. , 2012, Metabolism: clinical and experimental.
[59] H. Singer,et al. The non-excitable smooth muscle: Calcium signaling and phenotypic switching during vascular disease , 2008, Pflügers Archiv - European Journal of Physiology.
[60] G. Berglund,et al. Design and feasibility , 1993 .
[61] D. Dransfield,et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells , 2000, Peptides.
[62] K. Eriksson,et al. Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity , 2000, Journal of internal medicine.
[63] A. Gottsäter,et al. Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia. , 2005, International angiology : a journal of the International Union of Angiology.
[64] J. Bonnet,et al. Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration. , 2007, Cardiovascular research.
[65] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[66] J. Holst,et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.
[67] J. Holst,et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.
[68] Limei Liu,et al. Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension , 2015, Journal of cardiovascular pharmacology.
[69] J. Habener,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist* , 2000 .
[70] Li Yang,et al. Endothelin-1 regulates rat bone sialoprotein gene transcription. , 2010, Journal of oral science.
[71] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[72] C. Alpers,et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. , 1993, The Journal of clinical investigation.
[73] J. Molkentin,et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. , 2007, American journal of physiology. Cell physiology.
[74] T. Masaki. Historical review: Endothelin. , 2004, Trends in pharmacological sciences.
[75] L. Groop,et al. Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.
[76] S. Chakrabarti,et al. Alteration of Endothelins: A Common Pathogenetic Mechanism in Chronic Diabetic Complications , 2002, International journal of experimental diabetes research.
[77] Joshua J. Neumiller. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. , 2011, Clinical therapeutics.
[78] Reiko Ohmori,et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. , 2003, Atherosclerosis.
[79] C. Mcintosh,et al. Pleiotropic actions of the incretin hormones. , 2010, Vitamins and hormones.
[80] J. Holst,et al. Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[81] L. Groop,et al. Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes--a role for the transcription factor NFAT and phosphodiesterase 3B. , 2012, Biochemical and biophysical research communications.
[82] A. Bonev,et al. Opposing Actions of Inositol 1,4,5-Trisphosphate and Ryanodine Receptors on Nuclear Factor of Activated T-cells Regulation in Smooth Muscle* , 2002, The Journal of Biological Chemistry.
[83] M. Monami,et al. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.
[84] A. Gottsäter,et al. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. , 2005, Journal of vascular surgery.
[85] D. Drucker,et al. Cardiovascular biology of the incretin system. , 2012, Endocrine reviews.
[86] C. Mcintosh,et al. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene , 2010, Journal of Lipid Research.
[87] J. Holst,et al. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. , 2005, The Journal of clinical endocrinology and metabolism.
[88] Barbara Burwinkel,et al. Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. , 2007, Molecular nutrition & food research.
[89] W. Hsueh,et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. , 2003, The Journal of clinical investigation.
[90] L. Groop,et al. A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)–Botnia study , 2010, Diabetologia.
[91] Johanna Kuusisto,et al. Changes in Insulin Sensitivity and Insulin Release in Relation to Glycemia and Glucose Tolerance in 6,414 Finnish Men , 2009, Diabetes.
[92] JonathanGolledge,et al. Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis , 2004 .
[93] M. Laakso,et al. Association between liver insulin resistance and cardiovascular risk factors , 2012, Journal of internal medicine.
[94] M. Farrall,et al. European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.